Cardarine (GW-501516) monograph

Cardarine (GW-501516) Monograph

^[1]

This page preserves the structured raw monograph for TroponinIQ Base under the shared content policy. The content is factual reference material; it is not a production prompt or constant update. No Production target: directive was present in the source.

Curation Summary

• Class: Selective PPAR-δ (PPARβ/δ) agonist; investigational metabolic modulator
• Legal/regulatory status: Not FDA-approved. Not a controlled substance in the usual U.S. scheduled-drug sense, but it is an unapproved investigational compound and commonly sold as a research chemical. It is prohibited by WADA at all times under the Prohibited List because it is a PPARδ agonist and metabolic modulator; athletes are subject to anti-doping sanctions if detected.
• Routing: module 03 knowledge for mechanism, clinical/performance context, legal status, safety, and FAQ retrieval.
• Source hash: 894e5d396881853fd87b152237fa7275abb3117f6619b218ac24812840af8676

Overview Extract

Cardarine (GW-501516) is an investigational selective PPAR-δ agonist studied mainly for dyslipidemia and other metabolic indications, not an approved medicine. It became popular in bodybuilding circles because of its reputation for improving endurance and fat metabolism, but human evidence is limited and safety concerns are significant. It is prohibited in sport and is associated with carcinogenicity concerns in preclinical data.

Use-Case Anchors

• Primary goals: Investigated for dyslipidemia/hyperlipidemia, obesity, and cardiovascular-metabolic risk modification. In bodybuilding/performance settings it is used for perceived endurance support, fat-loss support, and improved lipid handling, but those uses are off-label, non-approved, and not well supported by high-quality human outcome data.

Safety / Legal Anchors

• Common side effects: Insomnia or sleep disruption, headache, nausea, GI upset, and possible changes in lipid markers are commonly discussed. Human adverse-event data are limited, so the true frequency and causality of these effects are not well established.

FAQ Anchors

• Q: Does Cardarine actually build muscle?

Source Text

Cardarine (GW-501516)

Overview

Cardarine (GW-501516) is an investigational selective PPAR-δ agonist studied mainly for dyslipidemia and other metabolic indications, not an approved medicine. It became popular in bodybuilding circles because of its reputation for improving endurance and fat metabolism, but human evidence is limited and safety concerns are significant. It is prohibited in sport and is associated with carcinogenicity concerns in preclinical data.

Pharmacokinetics & Mechanism

• Class: Selective PPAR-δ (PPARβ/δ) agonist; investigational metabolic modulator
• Mechanism of action: Activates PPAR-δ, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation, lipid metabolism, and energy homeostasis. In skeletal muscle and adipose tissue, PPAR-δ activation shifts substrate use toward fat oxidation and away from glucose, which is the biologic basis for the claimed endurance effects. Human performance-enhancement effects are not well established.
• Target(s): Primary target: peroxisome proliferator-activated receptor delta (PPARβ/δ; gene PPARD). Downstream pathways include fatty-acid oxidation and metabolic-gene transcription programs; AMPK-related metabolic effects are discussed in some literature but are not the primary direct target.
• Route(s) of administration: Oral only in the clinical/investigational setting. No approved injectable, transdermal, or other route exists; community use is typically oral liquid or capsules from research-chemical vendors.
• Onset: Not well established in humans. Metabolic gene-expression effects are expected over days rather than minutes to hours; performance effects, if any, would likely require repeated dosing.
• Half-life: About 16–24 hours in human studies and reviews, so once-daily dosing is commonly assumed. Some secondary sources and community writeups cite roughly 20–24 hours; exact human half-life is not robustly established and should be treated as approximate.
• Metabolism / clearance: Not well established from accessible authoritative sources in humans. Published summaries describe it as a small-molecule investigational compound with hepatic metabolism and systemic clearance; detailed human metabolic pathways are not clearly established in the sources reviewed.

Use-Cases & Dosing Strategies

• Primary goals: Investigated for dyslipidemia/hyperlipidemia, obesity, and cardiovascular-metabolic risk modification. In bodybuilding/performance settings it is used for perceived endurance support, fat-loss support, and improved lipid handling, but those uses are off-label, non-approved, and not well supported by high-quality human outcome data.
• Typical protocols: Clinical/investigational: there is no approved clinical dosing regimen, and publicly accessible human trial summaries do not establish a standard medical dose. Community/anecdotal: commonly reported oral dosing is about 5–20 mg/day, often 10–20 mg/day, used for 4–8 weeks; this is anecdotal and not validated as safe or effective. Do not present community dosing as clinical fact.
• Cycle length: Not established clinically. In community use, cycles are commonly reported at 4–8 weeks, sometimes up to 12 weeks, but longer use is especially hard to justify given safety concerns and lack of long-term human data.
• Common stacks: Community stacks often pair it with other performance-enhancing compounds such as testosterone or other anabolic agents, stimulants, or cutting agents. This is anecdotal and increases risk because it makes side-effect attribution harder and may worsen lipid, hepatic, and cardiovascular strain.
• Reconstitution / handling (peptides): Not a peptide; no reconstitution guidance applies. It is typically encountered as an oral solution or capsule in community markets, where product quality and concentration can be unreliable.
• Notes: Oral administration is the practical route. Community users often take it once daily based on the long approximate half-life; food effects and precise bioavailability are not well established in humans. Because product purity is uncertain outside regulated development, actual delivered dose may vary widely.

Clinical vs. community/anecdotal labeling is noted inline above. Community dosing is not established fact.

Side Effects & Safety / Legal

• Common side effects: Insomnia or sleep disruption, headache, nausea, GI upset, and possible changes in lipid markers are commonly discussed. Human adverse-event data are limited, so the true frequency and causality of these effects are not well established.
• Serious / less common: Preclinical carcinogenicity is the major red flag; this is the reason GW-501516 is widely treated as unsafe for non-research use. Potential serious risks also include liver enzyme abnormalities and broader metabolic/cardiovascular toxicity, but robust human incidence data are lacking. Long-term cancer risk in humans is not defined, which is part of the concern.
• Contraindications: Avoid in pregnancy and breastfeeding; avoid in anyone with active liver disease, significant dyslipidemia risk requiring medical management, or a personal/family cancer concern where risk tolerance is low. It should not be combined casually with other hepatotoxic or lipid-worsening agents. It is prohibited in competitive sport, so athletes subject to drug testing should not use it.
• Monitoring: If used despite risk, monitor ALT, AST, bilirubin, alkaline phosphatase, fasting lipid panel, CBC, fasting glucose/HbA1c, blood pressure, resting heart rate, and ideally any adverse symptom changes. Because human safety data are thin, there is no validated monitoring protocol that makes use “safe.”
• Legal / regulatory status: Not FDA-approved. Not a controlled substance in the usual U.S. scheduled-drug sense, but it is an unapproved investigational compound and commonly sold as a research chemical. It is prohibited by WADA at all times under the Prohibited List because it is a PPARδ agonist and metabolic modulator; athletes are subject to anti-doping sanctions if detected.

Chatbot FAQ

Q: Does Cardarine actually build muscle? A: Not in any reliable clinical sense. The pitch is better fat oxidation and endurance, not proven muscle gain.

Q: What dose do people use? A: Community reports usually cluster around 10–20 mg daily, but that is anecdotal, not a validated medical dose.

Q: How long does it stay in your system? A: Human half-life is commonly cited around 16–24 hours, but exact elimination data are not well established enough to give a precise, clinically trustworthy number.

Q: Is it safe for a cut? A: No one can honestly call it safe. The carcinogenicity concern and lack of good long-term human safety data are the problem.

Q: Is it banned in sport? A: Yes. WADA prohibits it.

Q: Can I stack it with testosterone or clenbuterol? A: People do, but that is a risk pile-up, not a smart evidence-based protocol.

Sources

• GW 501516 - PubChem — GW-501516 is a selective PPARδ agonist; investigated for obesity, lipid disorders, cardiovascular disease, and hyperlipidemia; max clinical phase reported as Phase 2; notes carcinogenic-agent role.
• Gene: PPARD - NCBI Gene — PPAR delta/PPARD is the receptor target associated with GW-501516's mechanism.
• WADA Prohibited List — GW-501516 is prohibited in sport under the WADA Prohibited List.
• GW-501516 - PubChem — Public summary of investigational status, therapeutic interests, and mechanism-related metabolism effects.

---

Data quality: Thin/experimental for human performance use. Mechanism and WADA status are solid; human dosing, onset, and metabolism are not well established. Half-life is commonly cited around 16–24 hours, but source-level precision is limited and long-term safety is a major unresolved conflict between hoped-for metabolic benefits and carcinogenicity concern.